Carolinas Health Systems clinics achieve EMRAM Stage 7

HIMSS Analytics has awarded 230 Carolinas Health System clinics with Stage 7 Ambulatory Awards. 

Developed in 2011, the EMR Ambulatory Adoption Model provides a methodology for evaluating the progress and impact of EMR systems for ambulatory facilities owned by hospitals in the HIMSS Analytics Database. Stage 7 represents the highest level of EHR adoption and indicates a health system’s advanced electronic patient record environment.

“As the first healthcare system to achieve Stage 7 for both hospitals and physician offices in North and South Carolina, it shows our commitment and dedication to our patients to provide access to quality health and care,” said Craig Richardville, FACHE, MBA, senior vice president and chief information officer. “Using electronic medical records to its fullest potential connects our clinical providers and our patients across all points of health and care. That means our patients experience a seamless integrated system of care from their work or home, to their physicians’ offices, to the emergency department, to the hospital, at all points of care. Most importantly, our EHR engages our patients to become full partners with their providers to live healthier lives.”

As of the fourth quarter of 2014, only 6.21 percent of the more than 30,000 U.S. ambulatory clinics in the HIMSS Analytics Database received the Stage 7 Ambulatory Award.

Carolinas Health System will be recognized at the 2015 Annual HIMSS Conference & Exhibition in April in Chicago. 


 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.